BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: André T, Shiu K, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZ, Marinello P, Diaz LA. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. N Engl J Med 2020;383:2207-18. [DOI: 10.1056/nejmoa2017699] [Cited by in Crossref: 179] [Cited by in F6Publishing: 99] [Article Influence: 89.5] [Reference Citation Analysis]
Number Citing Articles
1 Angerilli V, Galuppini F, Businello G, Dal Santo L, Savarino E, Realdon S, Guzzardo V, Nicolè L, Lazzarin V, Lonardi S, Loupakis F, Fassan M. MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. Biomedicines 2021;9:318. [PMID: 33801049 DOI: 10.3390/biomedicines9030318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kim N, Kim SM, Lee BJ, Choi BI, Yoon HS, Kang SH, Kim SH, Joo MK, Park J, Kim C. Detection of Microsatellite Instability in Colorectal Cancer Patients With a Plasma-Based Real-Time PCR Analysis. Front Pharmacol 2021;12:758830. [DOI: 10.3389/fphar.2021.758830] [Reference Citation Analysis]
3 André T, Cohen R. Immune checkpoint inhibitors in colorectal cancer: dream and reality. Lancet Gastroenterol Hepatol 2022;7:4-6. [PMID: 34688372 DOI: 10.1016/S2468-1253(21)00375-7] [Reference Citation Analysis]
4 Wookey V, Grothey A. Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. Therap Adv Gastroenterol 2021;14:17562848211024460. [PMID: 34262612 DOI: 10.1177/17562848211024460] [Reference Citation Analysis]
5 Oneda E, Zaniboni A. Adjuvant treatment of colon cancer with microsatellite instability - the state of the art. Crit Rev Oncol Hematol 2021;169:103537. [PMID: 34801698 DOI: 10.1016/j.critrevonc.2021.103537] [Reference Citation Analysis]
6 Koulouris A, Tsagkaris C, Nikolaou M. Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. Toxins (Basel) 2021;13:149. [PMID: 33672017 DOI: 10.3390/toxins13020149] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bordry N, Astaras C, Ongaro M, Goossens N, Frossard JL, Koessler T. Recent advances in gastrointestinal cancers. World J Gastroenterol 2021; 27(28): 4493-4503 [PMID: 34366620 DOI: 10.3748/wjg.v27.i28.4493] [Reference Citation Analysis]
8 Jin Z, Sinicrope FA. Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:300. [PMID: 33467526 DOI: 10.3390/cancers13020300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
9 Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol 2021;18:506-25. [PMID: 33864051 DOI: 10.1038/s41571-021-00495-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Huang A, Yang Y, Shi JY, Li YK, Xu JX, Cheng Y, Gu J. Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer. World J Gastrointest Surg 2021; 13(12): 1567-1583 [DOI: 10.4240/wjgs.v13.i12.1567] [Reference Citation Analysis]
11 Gallois C, Taieb J, Sabouret A, Broudin C, Karoui M, Garinet S, Zaanan A. Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report. Genes Chromosomes Cancer 2022;61:114-8. [PMID: 34773327 DOI: 10.1002/gcc.23012] [Reference Citation Analysis]
12 Torres-Jiménez J, Esteban-Villarrubia J, Ferreiro-Monteagudo R, Carrato A. Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist. Cancers (Basel) 2021;13:5938. [PMID: 34885047 DOI: 10.3390/cancers13235938] [Reference Citation Analysis]
13 Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev 2021;35:787-820. [PMID: 34074695 DOI: 10.1101/gad.348226.120] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yoshida T, Miki H, Satake H, Kobayashi T, Matsumi Y, Hamada M, Boku S, Shibata N, Ishida M, Sekimoto M. Pathological Complete Response of Clinical T4b Ascending Colon Cancer after Preoperative Chemotherapy Using Pembrolizumab. Case Rep Oncol 2021;14:1497-504. [PMID: 34899242 DOI: 10.1159/000519470] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ali O, Tolaymat M, Hu S, Xie G, Raufman JP. Overcoming Obstacles to Targeting Muscarinic Receptor Signaling in Colorectal Cancer. Int J Mol Sci 2021;22:E716. [PMID: 33450835 DOI: 10.3390/ijms22020716] [Reference Citation Analysis]
16 Yao D, Yu L, He W, Hu Y, Xu H, Yuan Y, Dai H. Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015-2019: an observational retrospective database analysis. BMJ Open 2021;11:e046166. [PMID: 34706945 DOI: 10.1136/bmjopen-2020-046166] [Reference Citation Analysis]
17 Gavignet C, Hobeika C, André T, Pocard M. Peritoneal recurrence of colorectal cancer with microsatellite instability: Is immunotherapy alone more effective than surgery? J Visc Surg 2021:S1878-7886(21)00143-0. [PMID: 34865996 DOI: 10.1016/j.jviscsurg.2021.09.005] [Reference Citation Analysis]
18 Dai Y, Zhao W, Yue L, Dai X, Rong D, Wu F, Gu J, Qian X. Perspectives on Immunotherapy of Metastatic Colorectal Cancer. Front Oncol 2021;11:659964. [PMID: 34178645 DOI: 10.3389/fonc.2021.659964] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Yu W, Tao Q, Zhang Y, Yi F, Feng L. Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer. J Oncol 2021;2021:9959946. [PMID: 34603452 DOI: 10.1155/2021/9959946] [Reference Citation Analysis]
20 Cremolini C, Vitale E, Rastaldo R, Giachino C. Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. Nanomaterials (Basel) 2021;11:661. [PMID: 33800368 DOI: 10.3390/nano11030661] [Reference Citation Analysis]
21 Gou Q, Xie Y, Zhang M, Chen Y, Shen Y. Synchronous Rectal Tumours with Different Molecular and Genetic Phenotypes Occurring in a Patient with Lynch Syndrome. Cancer Manag Res 2021;13:8009-15. [PMID: 34707409 DOI: 10.2147/CMAR.S333690] [Reference Citation Analysis]
22 Makita K, Hamamoto Y, Kanzaki H, Kataoka M, Yamamoto S, Nagasaki K, Ishikawa H, Takata N, Tsuruoka S, Uwatsu K, Kido T. Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study. Radiat Oncol 2021;16:225. [PMID: 34801042 DOI: 10.1186/s13014-021-01940-0] [Reference Citation Analysis]
23 Rogers JE, Dasari A. Pharmacotherapy for unresectable metastatic colorectal cancer. Expert Opin Pharmacother 2021;:1-10. [PMID: 34534031 DOI: 10.1080/14656566.2021.1982895] [Reference Citation Analysis]
24 Hu LF, Lan HR, Huang D, Li XM, Jin KT. Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand? Front Oncol 2021;11:769305. [PMID: 34888246 DOI: 10.3389/fonc.2021.769305] [Reference Citation Analysis]
25 Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, Kidera Y, Fukuoka K, Ito A, Chiba Y, Sakai K, Nishio K, Nakagawa K, Hayashi H. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann Oncol 2021:S0923-7534(21)04824-9. [PMID: 34843940 DOI: 10.1016/j.annonc.2021.11.009] [Reference Citation Analysis]
26 Ettrich TJ, Hüttner FJ, Lisson C, Gani C, Prasad V, Seufferlein T. [Multimodal, interdisciplinary therapeutic concepts for liver metastasized colorectal cancer]. Dtsch Med Wochenschr 2021;146:1468-77. [PMID: 34741292 DOI: 10.1055/a-1391-5273] [Reference Citation Analysis]
27 Shimura T. Novel Biomarkers of Gastrointestinal Cancer. Cancers (Basel) 2021;13:1501. [PMID: 33805858 DOI: 10.3390/cancers13071501] [Reference Citation Analysis]
28 Fanale D, Corsini LR, Scalia R, Brando C, Cucinella A, Madonia G, Dimino A, Filorizzo C, Barraco N, Bono M, Fiorino A, Magrin L, Sciacchitano R, Perez A, Russo TDB, Pantuso G, Russo A, Bazan V. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? Crit Rev Oncol Hematol 2022;:103597. [PMID: 35033663 DOI: 10.1016/j.critrevonc.2022.103597] [Reference Citation Analysis]
29 Dong C, Ding Y, Weng S, Li G, Huang Y, Hu H, Zhang Z, Zhang S, Yuan Y. Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020. Chin J Cancer Res 2021;33:302-7. [PMID: 34321827 DOI: 10.21147/j.issn.1000-9604.2021.03.02] [Reference Citation Analysis]
30 Deng Y; Chinese Southwest Oncology Group - the Committee of Colorectal Cancer. The "Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan (CPT-11), Oxaliplatin (LOHP), Continuous Infusion 5-Fluorouracil, and Leucovorin for Colorectal Cancer". Gastroenterol Rep (Oxf) 2021;9:279-89. [PMID: 34567559 DOI: 10.1093/gastro/goab033] [Reference Citation Analysis]
31 Cappellari M, Saia V, Pracucci G, Tassi R, Sallustio F, Nencini P, Zini A, Vallone S, Gasparotti R, Saletti A, Bergui M, Mangiafico S, Toni D; Italian Registry of Endovascular Treatment in Acute Stroke (IRETAS) Study Group. Different endovascular procedures for stroke with isolated M2-segment MCA occlusion: a real-world experience. J Thromb Thrombolysis 2021;51:1157-62. [PMID: 33491166 DOI: 10.1007/s11239-021-02378-7] [Reference Citation Analysis]
32 Susanti S, Wibowo S, Akbariani G, Yoshuantari N, Heriyanto DS, Ridwanuloh AM, Hariyatun H, Handaya AY, Kurnianda J, Hutajulu SH, Ilyas M. Molecular Analysis of Colorectal Cancers Suggests a High Frequency of Lynch Syndrome in Indonesia. Cancers 2021;13:6245. [DOI: 10.3390/cancers13246245] [Reference Citation Analysis]
33 Jin C, Zhu X, Huang X, Gong T, Wei Z, You J. Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis. J Comp Eff Res 2022. [PMID: 35023361 DOI: 10.2217/cer-2021-0134] [Reference Citation Analysis]
34 Aleksakhina SN, Imyanitov EN. Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. Int J Mol Sci 2021;22:10931. [PMID: 34681592 DOI: 10.3390/ijms222010931] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Gögenur M, Fransgård T, Krause TG, Thygesen LC, Gögenur I. Association of influenza vaccine and risk of recurrence in patients undergoing curative surgery for colorectal cancer. Acta Oncol 2021;60:1507-12. [PMID: 34459323 DOI: 10.1080/0284186X.2021.1967444] [Reference Citation Analysis]
36 Salkeni MA, Shin JY, Gulley JL. Resistance to Immunotherapy: Mechanisms and Means for Overcoming. Adv Exp Med Biol 2021;1342:45-80. [PMID: 34972962 DOI: 10.1007/978-3-030-79308-1_2] [Reference Citation Analysis]
37 Kasherman L, Karakasis K, Oza AM. With Our Powers Combined: Exploring PARP Inhibitors and Immunotherapy. Cancer J 2021;27:511-20. [PMID: 34904815 DOI: 10.1097/PPO.0000000000000557] [Reference Citation Analysis]
38 Dmello RS, To SQ, Chand AL. Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer. Int J Mol Sci 2021;22:2067. [PMID: 33669775 DOI: 10.3390/ijms22042067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Grecea M, Soritau O, Dulf D, Ciuleanu TE, Zdrenghea M. Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. Onco Targets Ther 2021;14:5275-91. [PMID: 34848970 DOI: 10.2147/OTT.S283892] [Reference Citation Analysis]
40 Mauri G, Bonazzina E, Amatu A, Tosi F, Bencardino K, Gori V, Massihnia D, Cipani T, Spina F, Ghezzi S, Siena S, Sartore-Bianchi A. The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:E137. [PMID: 33406649 DOI: 10.3390/cancers13010137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Casak SJ, Marcus L, Fashoyin-Aje L, Mushti SL, Cheng J, Shen YL, Pierce WF, Her L, Goldberg KB, Theoret MR, Kluetz PG, Pazdur R, Lemery SJ. FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma. Clin Cancer Res 2021;27:4680-4. [PMID: 33846198 DOI: 10.1158/1078-0432.CCR-21-0557] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Du W, Frankel TL, Green M, Zou W. IFNγ signaling integrity in colorectal cancer immunity and immunotherapy. Cell Mol Immunol 2021. [PMID: 34385592 DOI: 10.1038/s41423-021-00735-3] [Reference Citation Analysis]
43 Chen HH, Ke TW, Huang CW, Jiang JK, Chen CC, Hsieh YY, Teng HW, Lin BW, Liang YH, Su YL, Hsu HC, Kuan FC, Chou YH, Lin J, Lin BR, Chang YY, Wang JY. Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment. Front Oncol 2021;11:764912. [PMID: 34868987 DOI: 10.3389/fonc.2021.764912] [Reference Citation Analysis]
44 Grassi E, Corbelli J, Papiani G, Barbera MA, Gazzaneo F, Tamberi S. Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer. Front Oncol 2021;11:601722. [PMID: 34249672 DOI: 10.3389/fonc.2021.601722] [Reference Citation Analysis]
45 du Rusquec P, Le Tourneau C. Drug Development in Tissue-Agnostic Indications. Cancers (Basel) 2021;13:2758. [PMID: 34199382 DOI: 10.3390/cancers13112758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Ascierto PA, Bifulco C, Ciardiello F, Demaria S, Emens LA, Ferris R, Formenti SC, Galon J, Khleif SN, Kirchhoff T, McQuade J, Odunsi K, Patnaik A, Paulos CM, Taube JM, Timmerman J, Fox BA, Hwu P, Puzanov I. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). J Transl Med 2021;19:238. [PMID: 34078406 DOI: 10.1186/s12967-021-02895-2] [Reference Citation Analysis]
47 Yang W, Lei C, Song S, Jing W, Jin C, Gong S, Tian H, Guo T. Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies. Cancer Cell Int 2021;21:589. [PMID: 34727927 DOI: 10.1186/s12935-021-02299-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Höppener DJ, Galjart B, Nierop PMH, Buisman FE, van der Stok EP, Coebergh van den Braak RRJ, van Amerongen MJ, Balachandran VP, Jarnagin WR, Kingham TP, Doukas M, Shia J, Nagtegaal ID, Vermeulen PB, Koerkamp BG, Grünhagen DJ, de Wilt JHW, D'Angelica MI, Verhoef C. Histopathological Growth Patterns and Survival After Resection of Colorectal Liver Metastasis: An External Validation Study. JNCI Cancer Spectr 2021;5:pkab026. [PMID: 34056541 DOI: 10.1093/jncics/pkab026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Bui QL, Mas L, Hollebecque A, Tougeron D, de la Fouchardière C, Pudlarz T, Alouani E, Guimbaud R, Taieb J, André T, Colle R, Cohen R. Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer. Cancers 2022;14:406. [DOI: 10.3390/cancers14020406] [Reference Citation Analysis]
50 Park R, Lopes L, Lee S, Riano I, Saeed A. The prognostic and predictive impact of BRAF mutations in deficient mismatch repair/microsatellite instability-high colorectal cancer: systematic review/meta-analysis. Future Oncol 2021;17:4221-31. [PMID: 34323124 DOI: 10.2217/fon-2021-0552] [Reference Citation Analysis]
51 Yang J, Bi F, Gou H. Complete Pathologic Response After Concurrent Treatment with Pembrolizumab and Radiotherapy in Metastatic Colorectal Cancer: A Case Report. Onco Targets Ther 2021;14:2555-61. [PMID: 33880034 DOI: 10.2147/OTT.S298333] [Reference Citation Analysis]
52 Rao X, Jiang J, Liang Z, Zhang J, Zhuang Z, Qiu H, Luo H, Weng N, Wu X. Down-Regulated CLDN10 Predicts Favorable Prognosis and Correlates With Immune Infiltration in Gastric Cancer. Front Genet 2021;12:747581. [PMID: 34721537 DOI: 10.3389/fgene.2021.747581] [Reference Citation Analysis]
53 Csizmar CM, Ansell SM. Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma. Int J Mol Sci 2021;22:3302. [PMID: 33804869 DOI: 10.3390/ijms22073302] [Reference Citation Analysis]
54 Cani AK, Dolce EM, Darga EP, Hu K, Liu CJ, Pierce J, Bradbury K, Kilgour E, Aung K, Schiavon G, Carroll D, Carr TH, Klinowska T, Lindemann J, Marshall G, Rowlands V, Harrington EA, Barrett JC, Sathiyayogan N, Morrow C, Sero V, Armstrong AC, Baird R, Hamilton E, Im SA, Jhaveri K, Patel MR, Dive C, Tomlins SA, Udager AM, Hayes DF, Paoletti C. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection. Mol Oncol 2021. [PMID: 34866317 DOI: 10.1002/1878-0261.13150] [Reference Citation Analysis]
55 van der Heide DM, Turaga KK, Chan CHF, Sherman SK. Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer. J Surg Res 2021;266:104-12. [PMID: 33989889 DOI: 10.1016/j.jss.2021.03.040] [Reference Citation Analysis]
56 Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2021. [PMID: 34764464 DOI: 10.1038/s41571-021-00573-2] [Reference Citation Analysis]
57 Kim CW, Chon HJ, Kim C. Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer. Cancers (Basel) 2021;13:4906. [PMID: 34638390 DOI: 10.3390/cancers13194906] [Reference Citation Analysis]
58 Yang K, Han L, Wu S, Qu X, Li Q, Zhao C, Zhou J, Jin X, Wang Y, Yan D, Cheng Z, Hua Y, Zhang Y, Ge Y, Sun J, Deng W, Zhao L, Zhao Y. Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study. Cancer Immunol Immunother 2021. [PMID: 34689233 DOI: 10.1007/s00262-021-03083-3] [Reference Citation Analysis]
59 Kawakami H, Hironaka S, Esaki T, Chayama K, Tsuda M, Sugimoto N, Kadowaki S, Makiyama A, Machida N, Hirano H, Hirata K, Hara H, Yabusaki H, Komatsu Y, Muro K. An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers (Basel) 2021;13:805. [PMID: 33671871 DOI: 10.3390/cancers13040805] [Reference Citation Analysis]
60 Olivier R, Randrian V, Tougeron D, Saurin JC. Endoscopy to Diagnose and Prevent Digestive Cancers in Lynch Syndrome. Cancers (Basel) 2021;13:3505. [PMID: 34298719 DOI: 10.3390/cancers13143505] [Reference Citation Analysis]
61 Rüschoff J, Baretton G, Bläker H, Dietmaier W, Dietel M, Hartmann A, Horn LC, Jöhrens K, Kirchner T, Knüchel R, Mayr D, Merkelbach-Bruse S, Schildhaus HU, Schirmacher P, Tiemann M, Tiemann K, Weichert W, Büttner R. MSI testing : What's new? What should be considered? Pathologe 2021;42:110-8. [PMID: 34477921 DOI: 10.1007/s00292-021-00948-3] [Reference Citation Analysis]
62 Paspalj V, Polterauer S, Poetsch N, Reinthaller A, Grimm C, Bartl T. Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report. Gynecol Oncol Rep 2021;37:100817. [PMID: 34258357 DOI: 10.1016/j.gore.2021.100817] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Nakayama Y, Iijima T, Inokuchi T, Kojika E, Takao M, Takao A, Koizumi K, Horiguchi SI, Hishima T, Yamaguchi T. Clinicopathological features of sporadic MSI colorectal cancer and Lynch syndrome: a single-center retrospective cohort study. Int J Clin Oncol 2021. [PMID: 34148153 DOI: 10.1007/s10147-021-01968-y] [Reference Citation Analysis]
64 Walsh RJ, Tan DSP. The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives. J Clin Med 2021;10:4523. [PMID: 34640541 DOI: 10.3390/jcm10194523] [Reference Citation Analysis]
65 Jordan F, Trepel M, Claus R. Restoring immune mediated disease control by ipilimumab re-exposition in a heavily pre-treated patient with MSI-H mCRC. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.01.003] [Reference Citation Analysis]
66 Brochard C, Chicaud M, Colle R, Parc Y, Svrcek M. Réponse histologique complète d’un cancer colique métastatique de phénotype MisMatch Repair déficient/MicroSatellite Instable après immunothérapie : à propos d’un cas. Annales de Pathologie 2022. [DOI: 10.1016/j.annpat.2021.12.008] [Reference Citation Analysis]
67 Schledwitz A, Sundel MH, Alizadeh M, Hu S, Xie G, Raufman JP. Differential Actions of Muscarinic Receptor Subtypes in Gastric, Pancreatic, and Colon Cancer. Int J Mol Sci 2021;22:13153. [PMID: 34884958 DOI: 10.3390/ijms222313153] [Reference Citation Analysis]
68 Zhao Y, Liu L, Weng L. Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Front Pharmacol 2021;12:714483. [PMID: 34305619 DOI: 10.3389/fphar.2021.714483] [Reference Citation Analysis]
69 Tan LC, Liu WL, Zhu XL, Yu PC, Shi X, Han PZ, Zhang L, Lin LY, Semenov A, Wang Y, Ji QH, Ji DM, Wang YL, Qu N. Next-Generation Sequencing Enhances the Diagnosis Efficiency in Thyroid Nodules. Front Oncol 2021;11:677892. [PMID: 34322384 DOI: 10.3389/fonc.2021.677892] [Reference Citation Analysis]
70 Xu Z, Peng X, Kong Y, Cui Y, Li Y, Guo Y. The best strategy for metastatic colorectal cancer (mCRC) patients in second-line treatment: A network meta-analysis. Cancer Treat Res Commun 2021;29:100455. [PMID: 34619647 DOI: 10.1016/j.ctarc.2021.100455] [Reference Citation Analysis]
71 Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(8): 772-798 [PMID: 34457186 DOI: 10.4251/wjgo.v13.i8.772] [Reference Citation Analysis]
72 Fucà G, Corti F, Ambrosini M, Intini R, Salati M, Fenocchio E, Manca P, Manai C, Daniel F, Raimondi A, Morano F, Corallo S, Prisciandaro M, Spallanzani A, Quarà V, Belli C, Vaiani M, Curigliano G, Cremolini C, De Braud F, Di Bartolomeo M, Zagonel V, Lonardi S, Pietrantonio F. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer 2021;9:e002501. [PMID: 33849927 DOI: 10.1136/jitc-2021-002501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
73 Ciardiello D, Famiglietti V, Napolitano S, Esposito L, Pietrantonio F, Avallone A, Maiello E, Cremolini C, Troiani T, Martinelli E, Ciardiello F, Martini G. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.01.005] [Reference Citation Analysis]
74 Guan Y, Zhu X, Liang J, Wei M, Huang S, Pan X. Upregulation of HSPA1A/HSPA1B/HSPA7 and Downregulation of HSPA9 Were Related to Poor Survival in Colon Cancer. Front Oncol 2021;11:749673. [PMID: 34765552 DOI: 10.3389/fonc.2021.749673] [Reference Citation Analysis]
75 Ros J, Baraibar I, Martini G, Salvà F, Saoudi N, Cuadra-Urteaga JL, Dienstmann R, Tabernero J, Élez E. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Curr Treat Options Oncol 2021;22:113. [PMID: 34741675 DOI: 10.1007/s11864-021-00913-5] [Reference Citation Analysis]
76 Hasbullah HH, Musa M. Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward? Int J Mol Sci 2021;22:11941. [PMID: 34769370 DOI: 10.3390/ijms222111941] [Reference Citation Analysis]
77 Pyo J, Park HJ. Treatment Efficacy of Immune Checkpoint Inhibitors for Patients with Advanced or Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:3599. [PMID: 34441895 DOI: 10.3390/jcm10163599] [Reference Citation Analysis]
78 Gilson P, Merlin JL, Harlé A. Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA). Cancers (Basel) 2021;13:1491. [PMID: 33804907 DOI: 10.3390/cancers13071491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
79 Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian Cancer Immunotherapy and Personalized Medicine. Int J Mol Sci 2021;22:6532. [PMID: 34207103 DOI: 10.3390/ijms22126532] [Reference Citation Analysis]
80 Petrelli F, Morelli AM, Luciani A, Ghidini A, Solinas C. Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Targ Oncol. [DOI: 10.1007/s11523-021-00824-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
81 Lee HY, Woo IS. Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates. Cancers (Basel) 2021;13:4590. [PMID: 34572817 DOI: 10.3390/cancers13184590] [Reference Citation Analysis]
82 Huang Q, Jacquelot N, Preaudet A, Hediyeh-Zadeh S, Souza-Fonseca-Guimaraes F, McKenzie ANJ, Hansbro PM, Davis MJ, Mielke LA, Putoczki TL, Belz GT. Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival. Cancers (Basel) 2021;13:559. [PMID: 33535624 DOI: 10.3390/cancers13030559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
83 Du F, Liu Y. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. J Clin Lab Anal 2021;:e24141. [PMID: 34817097 DOI: 10.1002/jcla.24141] [Reference Citation Analysis]
84 Surana R, Pant S. Immunotherapy in Gastrointestinal Malignancies. Adv Exp Med Biol 2021;1342:259-72. [PMID: 34972968 DOI: 10.1007/978-3-030-79308-1_8] [Reference Citation Analysis]
85 Bonde A, Smith DA, Kikano E, Yoest JM, Tirumani SH, Ramaiya NH. Overview of serum and tissue markers in colorectal cancer: a primer for radiologists. Abdom Radiol (NY) 2021;46:5521-35. [PMID: 34415413 DOI: 10.1007/s00261-021-03243-0] [Reference Citation Analysis]
86 Hamre TR, Stougaard JK, Havelund BM, Jensen LH, Hansen TF. Re-exposure to immunotherapy in metastatic colon cancer: A case report. Clin Case Rep 2021;9:e04349. [PMID: 34194811 DOI: 10.1002/ccr3.4349] [Reference Citation Analysis]
87 Han Q, Liu S, Cui Z, Wang Q, Ma T, Jiang L, Li X, Dai G. Case Report and Literature Review: Diagnosis, Tailored Genetic Counseling and Cancer Prevention for a Locally Advanced dMMR/MSI-H/TMB-H Lung Cancer Patient With Concurrent Lynch Syndrome Mediated by a Rare PMS2 Splicing Variant (c.1144+1G>A). Front Genet 2022;12:799807. [DOI: 10.3389/fgene.2021.799807] [Reference Citation Analysis]
88 Damato A, Bergamo F, Antonuzzo L, Nasti G, Iachetta F, Romagnani A, Gervasi E, Larocca M, Pinto C. FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial. Front Oncol 2021;11:766500. [PMID: 34970487 DOI: 10.3389/fonc.2021.766500] [Reference Citation Analysis]
89 . Gemeinsame Stellungnahme der DGHO und DGVS zur Nutzenbewertung von Nivolumab (metastasiertes kolorektales Karzinom, dMMR oder MSI-H, vorbehandelte Patient*innen, Kombination mit Ipilimumab). Z Gastroenterol 2022;60:111-5. [DOI: 10.1055/a-1721-7018] [Reference Citation Analysis]
90 Randrian V, Evrard C, Tougeron D. Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies. Cancers (Basel) 2021;13:3063. [PMID: 34205397 DOI: 10.3390/cancers13123063] [Reference Citation Analysis]
91 Zhang J, Chen J, Shan B, Lin L, Dong J, Sun Q, Zhou Q, Han X. Clinical Significance and Prognostic Value of Human Soluble Resistance-Related Calcium-Binding Protein: A Pan-Cancer Analysis. Front Med (Lausanne) 2021;8:752619. [PMID: 34869449 DOI: 10.3389/fmed.2021.752619] [Reference Citation Analysis]
92 Kamposioras K, Ntellas P, Nikolaou M, Germetaki T, Gazouli I, Dadouli K, Zarkavelis G, Amylidi AL, Tolia M, Mauri D. Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature. JNCI Cancer Spectr 2021;5:pkab088. [PMID: 34926989 DOI: 10.1093/jncics/pkab088] [Reference Citation Analysis]
93 Chung C. Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation. J Oncol Pharm Pract 2021;:10781552211005525. [PMID: 33832365 DOI: 10.1177/10781552211005525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Howe JR. The impact of DNA testing on management of patients with colorectal cancer. Ann Gastroenterol Surg. [DOI: 10.1002/ags3.12526] [Reference Citation Analysis]
95 Waller J, Gu L, De Hoedt AM, Freedland SJ, Wang T, Amonkar M, Aurora-garg D, Liaw K, Wehn A, Klaassen Z. DNA mismatch repair and microsatellite instability in colorectal tumors: an observational study in the Veterans Affairs Health Care System. Future Oncology. [DOI: 10.2217/fon-2021-0874] [Reference Citation Analysis]
96 Seed LM. Horizon Scanning in Cancer Genomics: How Advances in Genomic Medicine Will Change Cancer Care Over the Next Decade. Curr Genet Med Rep 2021;:1-10. [PMID: 34306823 DOI: 10.1007/s40142-021-00200-7] [Reference Citation Analysis]
97 Cohen R, Colle R, Pudlarz T, Heran M, Duval A, Svrcek M, André T. Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. Cancers (Basel) 2021;13:1149. [PMID: 33800202 DOI: 10.3390/cancers13051149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
98 Jasmine F, Haq Z, Kamal M, Raza M, da Silva G, Gorospe K, Paul R, Strzempek P, Ahsan H, Kibriya MG. Interaction between Microsatellite Instability (MSI) and Tumor DNA Methylation in the Pathogenesis of Colorectal Carcinoma. Cancers (Basel) 2021;13:4956. [PMID: 34638440 DOI: 10.3390/cancers13194956] [Reference Citation Analysis]
99 Chaudhry S, Fields RC, Grierson PM, Lim KH. Combined Systemic and Hepatic Artery Infusion Pump Chemo-Therapy as a Liver-Directed Therapy for Colorectal Liver Metastasis-Review of Literature and Case Discussion. Cancers (Basel) 2021;13:1283. [PMID: 33805846 DOI: 10.3390/cancers13061283] [Reference Citation Analysis]
100 Ålgars A, Kemppinen L, Fair-Mäkelä R, Mustonen H, Haglund C, Jalkanen S. Stage I-IV Colorectal Cancer Prognosis Can Be Predicted by Type and Number of Intratumoral Macrophages and CLEVER-1+ Vessel Density. Cancers (Basel) 2021;13:5988. [PMID: 34885098 DOI: 10.3390/cancers13235988] [Reference Citation Analysis]
101 Zhu PF, Chen YW, Wang MX, Deng YY, Pan SY, Chen ZL, Yang L. Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review. Anticancer Drugs 2022;33:e822-7. [PMID: 34459462 DOI: 10.1097/CAD.0000000000001232] [Reference Citation Analysis]
102 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
103 Cox RE Jr, Mahipal A, Chakrabarti S. A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy. Cureus 2021;13:e14640. [PMID: 34055508 DOI: 10.7759/cureus.14640] [Reference Citation Analysis]
104 Parisi A, Porzio G, Pulcini F, Cannita K, Ficorella C, Mattei V, Delle Monache S. What Is Known about Theragnostic Strategies in Colorectal Cancer. Biomedicines 2021;9:140. [PMID: 33535557 DOI: 10.3390/biomedicines9020140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Daca Alvarez M, Quintana I, Terradas M, Mur P, Balaguer F, Valle L. The Inherited and Familial Component of Early-Onset Colorectal Cancer. Cells 2021;10:710. [PMID: 33806975 DOI: 10.3390/cells10030710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
106 Wooley JR, Penas-Prado M. Pediatric versus Adult Medulloblastoma: Towards a Definition That Goes beyond Age. Cancers (Basel) 2021;13:6313. [PMID: 34944933 DOI: 10.3390/cancers13246313] [Reference Citation Analysis]
107 Huang Y, Chen X, Wang L, Wang T, Tang X, Su X. Centromere Protein F (CENPF) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma. J Cancer 2021;12:2933-51. [PMID: 33854594 DOI: 10.7150/jca.52187] [Reference Citation Analysis]
108 Rochefort P, Desseigne F, Bonadona V, Dussart S, Coutzac C, Sarabi M, la Fouchardiere C. Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors. Immunotherapy 2021;13:1205-13. [PMID: 34494466 DOI: 10.2217/imt-2021-0024] [Reference Citation Analysis]
109 Stein MK, Oluoha O, Patel K, VanderWalde A. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. J Pers Med 2021;11:518. [PMID: 34198738 DOI: 10.3390/jpm11060518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Schildhaus HU, Weichert W. [Predictive diagnostics for checkpoint inhibitors]. Pathologe 2021;42:380-90. [PMID: 33956171 DOI: 10.1007/s00292-021-00939-4] [Reference Citation Analysis]
111 Park S, Lee C, Ku BM, Kim M, Park W, Kim NKD, Ahn M. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer. BMB Rep 2021;54:386-91. [DOI: 10.5483/bmbrep.2021.54.7.045] [Reference Citation Analysis]
112 Jiang Y, Liao HL, Chen LY. A Pan-Cancer Analysis of SLC12A5 Reveals Its Correlations with Tumor Immunity. Dis Markers 2021;2021:3062606. [PMID: 34630736 DOI: 10.1155/2021/3062606] [Reference Citation Analysis]
113 Botticelli A, Cirillo A, Pomati G, Cerbelli B, Scagnoli S, Roberto M, Gelibter A, Mammone G, Calandrella ML, Cerbelli E, Di Pietro FR, De Galitiis F, Lanzetta G, Cortesi E, Mezi S, Marchetti P. The role of opioids in cancer response to immunotherapy. J Transl Med 2021;19:119. [PMID: 33757546 DOI: 10.1186/s12967-021-02784-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Wong SK, Nebhan CA, Johnson DB. Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. Front Immunol 2021;12:786046. [PMID: 34868071 DOI: 10.3389/fimmu.2021.786046] [Reference Citation Analysis]
115 Shek D, Akhuba L, Carlino MS, Nagrial A, Moujaber T, Read SA, Gao B, Ahlenstiel G. Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes. Cancers (Basel) 2021;13:4345. [PMID: 34503155 DOI: 10.3390/cancers13174345] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Durinikova E, Buzo K, Arena S. Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges. J Exp Clin Cancer Res 2021;40:185. [PMID: 34090508 DOI: 10.1186/s13046-021-01981-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
117 Herbreteau G, Airaud F, Pierre-Noël E, Vallée A, Bézieau S, Théoleyre S, Blons H, Garinet S, Denis MG. MEM: An Algorithm for the Reliable Detection of Microsatellite Instability (MSI) on a Small NGS Panel in Colorectal Cancer. Cancers (Basel) 2021;13:4203. [PMID: 34439357 DOI: 10.3390/cancers13164203] [Reference Citation Analysis]
118 Pietrantonio F, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Curigliano G, Cremolini C, Ambrosini M, Ros J, Intini R, Nappo F, Damian S, Morano F, Fucà G, Overman M, Miceli R. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer 2021;9:e003370. [PMID: 34429334 DOI: 10.1136/jitc-2021-003370] [Reference Citation Analysis]
119 Guarini C, Grassi T, Pezzicoli G, Porta C. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. Int J Mol Sci 2021;22:6813. [PMID: 34202896 DOI: 10.3390/ijms22136813] [Reference Citation Analysis]
120 Miyashita N, Saito A. Organ Specificity and Heterogeneity of Cancer-Associated Fibroblasts in Colorectal Cancer. Int J Mol Sci 2021;22:10973. [PMID: 34681633 DOI: 10.3390/ijms222010973] [Reference Citation Analysis]
121 El Sissy C, Kirilovsky A, Zeitoun G, Marliot F, Haicheur N, Lagorce-Pagès C, Galon J, Pagès F. Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer. Cancers (Basel) 2021;13:1281. [PMID: 33805758 DOI: 10.3390/cancers13061281] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
122 Schledwitz A, Xie G, Raufman JP. Exploiting unique features of the gut-brain interface to combat gastrointestinal cancer. J Clin Invest 2021;131:143776. [PMID: 33998603 DOI: 10.1172/JCI143776] [Reference Citation Analysis]
123 Zhang L, Zhao Q, Mao L, Li H, Zhuang M, Wang J, Liu Y, Qi M, Du X, Xia Z, Sun N, Liu Q, Chen H, Zhang R. Bioinformatics Analyses Reveal the Prognostic Value and Biological Roles of SEPHS2 in Various Cancers. Int J Gen Med 2021;14:6059-76. [PMID: 34594130 DOI: 10.2147/IJGM.S328222] [Reference Citation Analysis]
124 Zhu M, Jin Z, Hubbard JM. Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers (Basel) 2021;13:651. [PMID: 33561950 DOI: 10.3390/cancers13040651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
125 Wang J, Xi Y, Zhao J, Rong X, Lu W, Wang Y, Mansour-ghanaei F. The Clinicopathological Characteristics and Prognoses of dMMR Gastric Adenocarcinoma Patients. Gastroenterology Research and Practice 2021;2021:1-11. [DOI: 10.1155/2021/4269781] [Reference Citation Analysis]
126 Hamada N, Maeda A, Takase-Minegishi K, Kirino Y, Sugiyama Y, Namkoong H, Horita N, Yoshimi R, Nakajima H; YCU irAE Working Group. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis. Front Immunol 2021;12:803410. [PMID: 34938300 DOI: 10.3389/fimmu.2021.803410] [Reference Citation Analysis]
127 Zhang H, Wu J, Liu Z, Gao J, Li S, Gao D. SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer. BioMed Research International 2022;2022:1-13. [DOI: 10.1155/2022/1398268] [Reference Citation Analysis]
128 Louie AD, Huntington K, Carlsen L, Zhou L, El-Deiry WS. Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics. Front Pharmacol 2021;12:747194. [PMID: 34737704 DOI: 10.3389/fphar.2021.747194] [Reference Citation Analysis]
129 Schlauch D, Fu X, Jones SF, Burris HA 3rd, Spigel DR, Reeves J, McKenzie AJ. Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precis Oncol 2021;5:1625-38. [PMID: 34994650 DOI: 10.1200/PO.21.00008] [Reference Citation Analysis]
130 Baik H, Lee HJ, Park J, Park HY, Park J, Lee S, Bae KB. Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report. Mol Clin Oncol 2021;15:243. [PMID: 34650810 DOI: 10.3892/mco.2021.2405] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Ren Y, Qian Y, Ai L, Xie Y, Gao Y, Zhuang Z, Chen J, Chen YX, Fang JY. TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity. Nat Commun 2021;12:5405. [PMID: 34518538 DOI: 10.1038/s41467-021-25662-9] [Reference Citation Analysis]
132 Stein A, Simnica D, Schultheiß C, Scholz R, Tintelnot J, Gökkurt E, von Wenserski L, Willscher E, Paschold L, Sauer M, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich TJ, Dörfel S, Al-Batran SE, Karthaus M, Pelzer U, Waberer L, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. J Immunother Cancer 2021;9:e002844. [PMID: 34315821 DOI: 10.1136/jitc-2021-002844] [Reference Citation Analysis]
133 Baraibar I, Mirallas O, Saoudi N, Ros J, Salvà F, Tabernero J, Élez E. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:6311. [PMID: 34944931 DOI: 10.3390/cancers13246311] [Reference Citation Analysis]
134 Chen M, Linstra R, van Vugt MATM. Genomic instability, inflammatory signaling and response to cancer immunotherapy. Biochim Biophys Acta Rev Cancer 2021;1877:188661. [PMID: 34800547 DOI: 10.1016/j.bbcan.2021.188661] [Reference Citation Analysis]
135 Biller LH, Schrag D. A Review of the Diagnosis and Treatment of Metastatic Colorectal Cancer-Reply. JAMA 2021;325:2405. [PMID: 34129001 DOI: 10.1001/jama.2021.6027] [Reference Citation Analysis]
136 Chen Y, Zheng X, Wu C. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. Front Immunol 2021;12:792691. [PMID: 34925375 DOI: 10.3389/fimmu.2021.792691] [Reference Citation Analysis]
137 Cortés-Guiral D, Hübner M, Alyami M, Bhatt A, Ceelen W, Glehen O, Lordick F, Ramsay R, Sgarbura O, Van Der Speeten K, Turaga KK, Chand M. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers 2021;7:91. [PMID: 34916522 DOI: 10.1038/s41572-021-00326-6] [Reference Citation Analysis]
138 Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. Cancers (Basel) 2021;13:2296. [PMID: 34064974 DOI: 10.3390/cancers13102296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
139 O'Shea R, Rankin NM, Kentwell M, Gleeson M, Tucker KM, Hampel H, Taylor N, Lewis S. Stakeholders' views of integrating universal tumour screening and genetic testing for colorectal and endometrial cancer into routine oncology. Eur J Hum Genet 2021. [PMID: 33811254 DOI: 10.1038/s41431-021-00871-4] [Reference Citation Analysis]
140 Bayle A, Hollebecque A, Pistilli B, Massard C, Marabelle A. Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks. Eur J Cancer 2021;156:217-21. [PMID: 34400059 DOI: 10.1016/j.ejca.2021.06.044] [Reference Citation Analysis]
141 Tong K, Kothari OA, Haro KS, Panda A, Bandari MM, Carrick JN, Hur JJ, Zhang L, Chan CS, Xing J, Gatza ML, Ganesan S, Verzi MP. SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis. Oncogene 2021;40:6034-48. [PMID: 34453124 DOI: 10.1038/s41388-021-01997-x] [Reference Citation Analysis]
142 Bai J, Chen H, Bai X. Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment. J Clin Lab Anal 2021;35:e23810. [PMID: 33938589 DOI: 10.1002/jcla.23810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Galbraith NJ, Wood C, Steele CW. Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies. Cancers (Basel) 2021;13:3566. [PMID: 34298779 DOI: 10.3390/cancers13143566] [Reference Citation Analysis]
144 Alawawdeh A, Piantadosi C, Townsend AR, Karapetis CS, Padbury R, Roy AC, Moore J, Maddern G, Roder D, Smith A, Price TJ. Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry. Target Oncol 2021. [PMID: 34822070 DOI: 10.1007/s11523-021-00856-9] [Reference Citation Analysis]
145 Lentz RW, Messersmith WA. Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases. J Clin Oncol 2021;39:3887-9. [PMID: 34541862 DOI: 10.1200/JCO.21.01993] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
146 Lin H, Xia L, Lian J, Chen Y, Zhang Y, Zhuang Z, Cai H, You J, Guan G. Delineation of colorectal cancer ligand-receptor interactions and their roles in the tumor microenvironment and prognosis. J Transl Med 2021;19:497. [PMID: 34876143 DOI: 10.1186/s12967-021-03162-0] [Reference Citation Analysis]
147 Rhyner Agocs G, Assarzadegan N, Kirsch R, Dawson H, Galván JA, Lugli A, Zlobec I, Berger MD. LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. J Pers Med 2021;11:749. [PMID: 34442393 DOI: 10.3390/jpm11080749] [Reference Citation Analysis]
148 Liposits G, Eshøj HR, Möller S, Winther SB, Skuladottir H, Ryg J, Hofsli E, Shah CH, Poulsen LØ, Berglund Å, Qvortrup C, Österlund P, Glimelius B, Sorbye H, Pfeiffer P. Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study. Cancers (Basel) 2021;13:2604. [PMID: 34073363 DOI: 10.3390/cancers13112604] [Reference Citation Analysis]
149 Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers (Basel) 2021;13:2638. [PMID: 34072037 DOI: 10.3390/cancers13112638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Hsu HC, Huang KC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang TS, Chen CC, Chao Y, Teng HW. Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread. Sci Rep 2021;11:15370. [PMID: 34321583 DOI: 10.1038/s41598-021-94968-x] [Reference Citation Analysis]
151 Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol 2022;14:175883592110727. [DOI: 10.1177/17588359211072703] [Reference Citation Analysis]
152 Zhang Y, La B, Liang B, Gu Y. Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. Life (Basel) 2021;11:1277. [PMID: 34833153 DOI: 10.3390/life11111277] [Reference Citation Analysis]
153 Wu W, Liu Y, Zeng S, Han Y, Shen H. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes. J Hematol Oncol 2021;14:160. [PMID: 34620200 DOI: 10.1186/s13045-021-01166-3] [Reference Citation Analysis]
154 Hamed RA, Marks S, Mcelligott H, Kalachand R, Ibrahim H, Atyani S, Korpanty G, Osman N. Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre). Mol Clin Oncol 2022;16:40. [PMID: 35003738 DOI: 10.3892/mco.2021.2472] [Reference Citation Analysis]
155 Chan DKH, Buczacki SJA. Tumour heterogeneity and evolutionary dynamics in colorectal cancer. Oncogenesis 2021;10:53. [PMID: 34272358 DOI: 10.1038/s41389-021-00342-x] [Reference Citation Analysis]
156 Papamichail M, Pizanias M, Heaton ND, M P, M P, Nd H. Minimizing the risk of small-for-size syndrome after liver surgery. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00230-7. [PMID: 34961675 DOI: 10.1016/j.hbpd.2021.12.005] [Reference Citation Analysis]
157 Rüschoff J, Baretton G, Bläker H, Dietmaier W, Dietel M, Hartmann A, Horn LC, Jöhrens K, Kirchner T, Knüchel R, Mayr D, Merkelbach-Bruse S, Schildhaus HU, Schirmacher P, Tiemann M, Tiemann K, Weichert W, Büttner R. [MSI testing : What is new? What should be considered? German version]. Pathologe 2021;42:414-23. [PMID: 34043067 DOI: 10.1007/s00292-021-00944-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Zhou YX, Chen P, Sun YT, Zhang B, Qiu MZ. Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting. Front Oncol 2021;11:698732. [PMID: 34621668 DOI: 10.3389/fonc.2021.698732] [Reference Citation Analysis]
159 Toor SM, Sasidharan Nair V, Murshed K, Abu Nada M, Elkord E. Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors. Vaccines (Basel) 2021;9:64. [PMID: 33477864 DOI: 10.3390/vaccines9010064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Fiorillo C, Schena CA, Quero G, Laterza V, Pugliese D, Privitera G, Rosa F, Schepis T, Salvatore L, Di Stefano B, Larosa L, Minordi LM, Natale L, Tortora G, Armuzzi A, Alfieri S. Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis. Cancers (Basel) 2021;13:574. [PMID: 33540674 DOI: 10.3390/cancers13030574] [Reference Citation Analysis]
161 Gallon R, Gawthorpe P, Phelps RL, Hayes C, Borthwick GM, Santibanez-Koref M, Jackson MS, Burn J. How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies. Cancers (Basel) 2021;13:406. [PMID: 33499123 DOI: 10.3390/cancers13030406] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
162 Giordano G, Parcesepe P, Bruno G, Piscazzi A, Lizzi V, Remo A, Pancione M, D'Andrea MR, De Santis E, Coppola L, Pietrafesa M, Fersini A, Ambrosi A, Landriscina M. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. Int J Mol Sci 2021;22:7717. [PMID: 34299337 DOI: 10.3390/ijms22147717] [Reference Citation Analysis]
163 Wang C, Sandhu J, Ouyang C, Ye J, Lee PP, Fakih M. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. JAMA Netw Open 2021;4:e2118416. [PMID: 34369992 DOI: 10.1001/jamanetworkopen.2021.18416] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
164 Roudko V, Cimen Bozkus C, Greenbaum B, Lucas A, Samstein R, Bhardwaj N. Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines. Front Immunol 2021;12:757804. [PMID: 34630437 DOI: 10.3389/fimmu.2021.757804] [Reference Citation Analysis]
165 Talbot A, O'Donovan E, Berkley E, Nolan C, Clarke R, Gallagher D. The contribution of Lynch syndrome to early onset malignancy in Ireland. BMC Cancer 2021;21:617. [PMID: 34039291 DOI: 10.1186/s12885-021-08263-z] [Reference Citation Analysis]
166 Han KT, Kim S. Post-Diagnostic Statin Use Reduces Mortality in South Korean Patients with Dyslipidemia and Gastrointestinal Cancer. J Clin Med 2021;10:2361. [PMID: 34072162 DOI: 10.3390/jcm10112361] [Reference Citation Analysis]
167 Reischer A, Kruger S, von Bergwelt-Baildon M. [A decade of checkpoint inhibitors: current standard of care and future trends]. Dtsch Med Wochenschr 2021;146:1108-18. [PMID: 34448187 DOI: 10.1055/a-1303-8820] [Reference Citation Analysis]
168 Xie P, Zheng H, Chen H, Wei K, Pan X, Xu Q, Wang Y, Tang C, Gevaert O, Meng X. Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival. BMC Cancer 2021;21:1246. [PMID: 34798858 DOI: 10.1186/s12885-021-08944-9] [Reference Citation Analysis]
169 Lee JY. [The Efficacy of Immune Checkpoint Inhibitors as First-line Treatment in Microsatellite-instability-high Metastatic Colorectal Cancer]. Korean J Gastroenterol 2021;77:261-2. [PMID: 34035206 DOI: 10.4166/kjg.2021.062] [Reference Citation Analysis]
170 Auclin E, Vuagnat P, Smolenschi C, Taieb J, Adeva J, Nebot-Bral L, Garcia de Herreros M, Vidal Tocino R, Longo-Muñoz F, El Dakdouki Y, Martín-Romano P, Gaba L, Saurí T, Oliveres H, Castañón E, Garcia-Carbonero R, Besse B, Massard C, Mezquita L, Hollebecque A. Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. Cancers (Basel) 2021;13:3776. [PMID: 34359675 DOI: 10.3390/cancers13153776] [Reference Citation Analysis]
171 Ikoma T, Shimokawa M, Kotaka M, Matsumoto T, Nagai H, Boku S, Shibata N, Yasui H, Satake H. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. BMC Cancer 2021;21:518. [PMID: 33962575 DOI: 10.1186/s12885-021-08271-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
172 Salewski I, Henne J, Engster L, Schneider B, Lemcke H, Skorska A, Berlin P, Henze L, Junghanss C, Maletzki C. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors. Int J Mol Sci 2021;22:5990. [PMID: 34206051 DOI: 10.3390/ijms22115990] [Reference Citation Analysis]
173 Cancanelli L, Rivano M, Di Spazio L, Chiumente M, Mengato D, Messori A. Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials. Cureus 2021;13:e19893. [PMID: 34966607 DOI: 10.7759/cureus.19893] [Reference Citation Analysis]
174 Xu H, Xu Q, Yin L. Prognostic value of tumor immune cell infiltration patterns in colon adenocarcinoma based on systematic bioinformatics analysis. Cancer Cell Int 2021;21:344. [PMID: 34217290 DOI: 10.1186/s12935-021-02048-x] [Reference Citation Analysis]
175 Koopman M, Pinto C, Bodoky G, Garcia-carbonero R, Marti F, Bachet J. Rationale and design of the PROMETCO study: a real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective. Future Oncology. [DOI: 10.2217/fon-2021-1333] [Reference Citation Analysis]
176 Meltzer S, Torgunrud A, Abrahamsson H, Solbakken AM, Flatmark K, Dueland S, Bakke KM, Bousquet PA, Negård A, Johansen C, Lyckander LG, Larsen FO, Schou JV, Redalen KR, Ree AH. The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer. Br J Cancer 2021;125:240-6. [PMID: 33837301 DOI: 10.1038/s41416-021-01377-y] [Reference Citation Analysis]
177 Chongqing T, Sini L, Xiaohui Z, Liubao P, Ye P, Shuxia Q, Liting W, Meiyu W, Xiaomin W. Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer. Front Pharmacol 2021;12:802942. [PMID: 34970153 DOI: 10.3389/fphar.2021.802942] [Reference Citation Analysis]
178 Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol 2022;40:161-70. [PMID: 34637336 DOI: 10.1200/JCO.21.01015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
179 Touati R, Cohen R. [Drug Approval: Nivolumab plus ipilimumab for patients with MSI -high metastatic colorectal cancer previously treated with 5-fluorouracilchemotherapy]. Bull Cancer 2021:S0007-4551(21)00392-1. [PMID: 34756719 DOI: 10.1016/j.bulcan.2021.08.010] [Reference Citation Analysis]
180 Tu SM, Zhang M, Wood CG, Pisters LL. Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity. Cancers (Basel) 2021;13:4006. [PMID: 34439162 DOI: 10.3390/cancers13164006] [Reference Citation Analysis]
181 Yang H, Ma W, Sun B, Fan L, Xu K, Hall SRR, Al-Hurani MF, Schmid RA, Peng RW, Hida T, Wang Z, Yao F. Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients. Transl Lung Cancer Res 2021;10:3807-22. [PMID: 34733630 DOI: 10.21037/tlcr-21-734] [Reference Citation Analysis]
182 Nagayama S, Low SK, Kiyotani K, Nakamura Y. Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. Cancers (Basel) 2021;13:4803. [PMID: 34638288 DOI: 10.3390/cancers13194803] [Reference Citation Analysis]
183 Duffy MJ, Crown J. Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer. JPM 2022;12:99. [DOI: 10.3390/jpm12010099] [Reference Citation Analysis]
184 Noepel-Duennebacke S, Juette H, Schulmann K, Graeven U, Porschen R, Stoehlmacher J, Hegewisch-Becker S, Raulf A, Arnold D, Reinacher-Schick A, Tannapfel A. Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials. J Cancer Res Clin Oncol 2021;147:3063-72. [PMID: 33675399 DOI: 10.1007/s00432-021-03559-w] [Reference Citation Analysis]
185 Ni K, Zhan Y, Liu Z, Zhao XZ, Wang W, Wang G, Zhang Z, Li G, Zhang X, Zhang C. Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients. J Surg Oncol 2021. [PMID: 34918842 DOI: 10.1002/jso.26771] [Reference Citation Analysis]
186 Raimondi A, Palermo F, Prisciandaro M, Aglietta M, Antonuzzo L, Aprile G, Berardi R, Cardellino GG, De Manzoni G, De Vita F, Di Maio M, Fornaro L, Frassineti GL, Granetto C, Iachetta F, Lonardi S, Murialdo R, Ongaro E, Pucci F, Ratti M, Silvestris N, Smiroldo V, Spallanzani A, Strippoli A, Tamberi S, Tamburini E, Zaniboni A, Di Bartolomeo M, Cremolini C, Sposito C, Mazzaferro V, Pietrantonio F. TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers (Basel) 2021;13:2839. [PMID: 34200267 DOI: 10.3390/cancers13112839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Das A, Sudhaman S, Morgenstern D, Coblentz A, Chung J, Stone SC, Alsafwani N, Liu ZA, Karsaneh OAA, Soleimani S, Ladany H, Chen D, Zatzman M, Cabric V, Nobre L, Bianchi V, Edwards M, Sambira Nahum LC, Ercan AB, Nabbi A, Constantini S, Dvir R, Yalon-Oren M, Campino GA, Caspi S, Larouche V, Reddy A, Osborn M, Mason G, Lindhorst S, Bronsema A, Magimairajan V, Opocher E, De Mola RL, Sabel M, Frojd C, Sumerauer D, Samuel D, Cole K, Chiaravalli S, Massimino M, Tomboc P, Ziegler DS, George B, Van Damme A, Hijiya N, Gass D, McGee RB, Mordechai O, Bowers DC, Laetsch TW, Lossos A, Blumenthal DT, Sarosiek T, Yen LY, Knipstein J, Bendel A, Hoffman LM, Luna-Fineman S, Zimmermann S, Scheers I, Nichols KE, Zapotocky M, Hansford JR, Maris JM, Dirks P, Taylor MD, Kulkarni AV, Shroff M, Tsang DS, Villani A, Xu W, Aronson M, Durno C, Shlien A, Malkin D, Getz G, Maruvka YE, Ohashi PS, Hawkins C, Pugh TJ, Bouffet E, Tabori U. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat Med 2022. [PMID: 34992263 DOI: 10.1038/s41591-021-01581-6] [Reference Citation Analysis]
188 Pansy K, Uhl B, Krstic J, Szmyra M, Fechter K, Santiso A, Thüminger L, Greinix H, Kargl J, Prochazka K, Feichtinger J, Deutsch AJ. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. Int J Mol Sci 2021;22:13311. [PMID: 34948104 DOI: 10.3390/ijms222413311] [Reference Citation Analysis]
189 Alkan A, Hofving T, Angenete E, Yrlid U. Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients. Biomark Res 2021;9:60. [PMID: 34321074 DOI: 10.1186/s40364-021-00313-9] [Reference Citation Analysis]
190 Nöpel-Dünnebacke S, Conradi LC, Reinacher-Schick A, Ghadimi M. [Influence of molecular markers on oncological surgery of colorectal cancer]. Chirurg 2021;92:986-95. [PMID: 34448902 DOI: 10.1007/s00104-021-01486-7] [Reference Citation Analysis]
191 Chandra R, Karalis JD, Liu C, Murimwa GZ, Voth Park J, Heid CA, Reznik SI, Huang E, Minna JD, Brekken RA. The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis. Cancers (Basel) 2021;13:6206. [PMID: 34944826 DOI: 10.3390/cancers13246206] [Reference Citation Analysis]
192 Zhou C, Chen S, Xu F, Wei J, Zhou X, Wu Z, Zhao L, Liu J, Guo W. Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing. Ann Transl Med 2021;9:1437. [PMID: 34733989 DOI: 10.21037/atm-21-4227] [Reference Citation Analysis]
193 Busch E, Ahadova A, Kosmalla K, Bohaumilitzky L, Pfuderer PL, Ballhausen A, Witt J, Wittemann JN, Bläker H, Holinski-Feder E, Jäger D, von Knebel Doeberitz M, Haag GM, Kloor M. Beta-2-microglobulin Mutations Are Linked to a Distinct Metastatic Pattern and a Favorable Outcome in Microsatellite-Unstable Stage IV Gastrointestinal Cancers. Front Oncol 2021;11:669774. [PMID: 34168989 DOI: 10.3389/fonc.2021.669774] [Reference Citation Analysis]
194 Tse BCY, Welham Z, Engel AF, Molloy MP. Genomic, Microbial and Immunological Microenvironment of Colorectal Polyps. Cancers (Basel) 2021;13:3382. [PMID: 34298598 DOI: 10.3390/cancers13143382] [Reference Citation Analysis]
195 Sumransub N, Vantanasiri K, Prakash A, Lou E. Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success? Mol Ther Oncolytics 2021;22:1-12. [PMID: 34307839 DOI: 10.1016/j.omto.2021.05.001] [Reference Citation Analysis]
196 Britten CM, Shalabi A, Hoos A. Industrializing engineered autologous T cells as medicines for solid tumours. Nat Rev Drug Discov 2021;20:476-88. [PMID: 33833444 DOI: 10.1038/s41573-021-00175-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
197 Folprecht G, Reinacher-Schick A, Weitz J, Lugnier C, Kraeft AL, Wisser S, Aust DE, Weiss L, von Bubnoff N, Kramer M, Thiede C, Tannapfel A. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). Clin Colorectal Cancer 2021:S1533-0028(21)00091-8. [PMID: 34772609 DOI: 10.1016/j.clcc.2021.09.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Gruijs M, Braster R, Overdijk MB, Hellingman T, Verploegen S, Korthouwer R, van der Wilk BJ, Parren PWHI, van der Vliet HJ, Bögels M, van Egmond M. Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells. J Oncol 2022;2022:3577928. [PMID: 35035479 DOI: 10.1155/2022/3577928] [Reference Citation Analysis]
199 Lonati C, Necchi A, Gómez Rivas J, Afferi L, Laukhtina E, Martini A, Ventimiglia E, Colombo R, Gandaglia G, Salonia A, Briganti A, Montorsi F, Mattei A, Simeone C, Carlo MI, Shariat SF, Spiess PE, Moschini M; European Association of Urology Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group, the Global Society of Rare Genitourinary Tumors GSRGT. Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors. Eur Urol Oncol 2021:S2588-9311(21)00189-9. [PMID: 34896051 DOI: 10.1016/j.euo.2021.11.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Imyanitov E, Kuligina E. Molecular testing for colorectal cancer: Clinical applications. World J Gastrointest Oncol 2021; 13(10): 1288-1301 [PMID: 34721767 DOI: 10.4251/wjgo.v13.i10.1288] [Reference Citation Analysis]
201 Guo M, Jin N, Pawlik T, Cloyd JM. Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature. World J Gastrointest Oncol 2021; 13(9): 1043-1061 [PMID: 34616511 DOI: 10.4251/wjgo.v13.i9.1043] [Reference Citation Analysis]